In recent years, interest in testosterone replacement therapy for the management of male hypogonadism has grown significantly.This development has paralleled increased public awareness of the signs and symptoms of hypogonadism (also known as low T or low serum testosterone) and the opportunity to address this problem with therapeutic interventions.Conventionally, medical treatment of hypogonadism has been met with various formulations of exogenous testosterone therapies, albeit such therapies do carry limitations.Limitations range from challenges with therapeutic delivery to possible adverse effects.